ADVM Stock Price, Adverum Biotechnologies Quote, Chart

Market Summary

USD9.20-0.19

Delayed

-2.02%

ADVM Stock Price

View Fullscreen

ADVM RSI Chart

ADVM Valuation

Market Cap

190.9M

Price/Earnings (Trailing)

-1.63

Price/Sales (Trailing)

53.04

EV/EBITDA

-1.03

Price/Free Cashflow

-2.08

ADVM Price/Sales (Trailing)

ADVM Profitability

EBT Margin

-3284.53%

Return on Equity

-140.37%

Return on Assets

-67.72%

Free Cashflow Yield

-48.03%

ADVM Fundamentals

ADVM Revenue

Revenue (TTM)

3.6M

Rev. Growth (Yr)

-100%

ADVM Earnings

Earnings (TTM)

-117.2M

Earnings Growth (Yr)

27.56%

Earnings Growth (Qtr)

27.89%

Breaking Down ADVM Revenue

Last 7 days

-18.9%

Last 30 days

-37.2%

Last 90 days

-2.1%

Trailing 12 Months

12.5%

How does ADVM drawdown profile look like?

ADVM Financial Health

Current Ratio

4.13

ADVM Investor Care

Shares Dilution (1Y)

1.30%

Diluted EPS (TTM)

-11.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	5.9M	5.2M	4.4M	3.6M
2022	0	0	0	6.7M
2021	3.6M	5.5M	6.5M	7.5M
2019	0	0	1.6M	2.6M
2018	7.5M	7.6M	7.9M	7.5M
2017	1.7M	1.8M	1.9M	1.8M
2016	2.4M	2.5M	1.9M	1.5M
2015	745.0K	813.0K	1.6M	2.3M
2014	210.0K	195.0K	369.0K	572.0K
2013	142.5K	255.0K	367.5K	480.0K
2012	0	0	0	30.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Adverum Biotechnologies Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 07, 2024	lupher, jr. mark l.	bought	175,500	1.35	130,000	-
Feb 07, 2024	scopa james paul	bought	135,000	1.35	100,000	-
Sep 15, 2023	seyedkazemi setareh	sold	-9,429	1.5206	-6,201	chief development officer
Jun 07, 2023	rubinstein linda m	bought	145,490	1.4549	100,000	chief financial officer
Mar 15, 2023	soparkar peter	sold	-10,442	0.7816	-13,360	chief operating officer
Mar 15, 2023	riley brigit	sold	-5,704	0.7816	-7,299	chief scientific officer
Mar 15, 2023	fischer laurent	sold	-32,232	0.7816	-41,239	ceo, president and director
Sep 19, 2022	beckman richard	sold	-4,569	1.0697	-4,272	chief medical officer
Sep 19, 2022	soparkar peter	sold	-14,232	1.0697	-13,305	see remarks section
Sep 19, 2022	seyedkazemi setareh	sold	-6,479	1.0696	-6,058	chief development officer

Which funds bought or sold ADVM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Allworth Financial LP	sold off	-100	-16.00	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-29,821	-	-%
Apr 25, 2024	GHP Investment Advisors, Inc.	new	-	283	283	-%
Apr 25, 2024	GHP Investment Advisors, Inc.	sold off	-100	-151	-	-%
Apr 25, 2024	Allworth Financial LP	new	-	29.00	29.00	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-1,000	-	-%
Apr 24, 2024	Assenagon Asset Management S.A.	new	-	5,072,290	5,072,290	0.01%
Apr 24, 2024	BML Capital Management, LLC	new	-	11,780,300	11,780,300	7.77%
Apr 24, 2024	BML Capital Management, LLC	sold off	-100	-3,428,440	-	-%
Apr 22, 2024	Vivo Capital, LLC	new	-	21,210,000	21,210,000	1.67%

Are Funds Buying or Selling ADVM?

Are funds buying ADVM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ADVM

No. of Funds

Unveiling Adverum Biotechnologies Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 22, 2024	logos global management lp	7.2%	1.5e+07	SC 13G
Feb 15, 2024	tcg crossover gp ii, llc	9.9%	20,763,572	SC 13G
Feb 14, 2024	vivo opportunity fund holdings, l.p.	7.2%	1.5e+07	SC 13G
Feb 14, 2024	commodore capital lp	9.9%	1e+07	SC 13G/A
Feb 14, 2024	venrock healthcare capital partners iii, l.p.	7.5%	15,564,213	SC 13G/A
Feb 13, 2024	bank of america corp /de/	4.4%	4,425,895	SC 13G/A
Feb 12, 2024	morgan stanley	5.1%	5,150,496	SC 13G/A
Feb 09, 2024	frazier life sciences public fund, l.p.	2.4%	5,003,125	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 07, 2024	bml investment partners, l.p.	2.2%	4,554,252	SC 13G/A

Recent SEC filings of Adverum Biotechnologies Inc

View All Filings

Date Filed	Form Type	Document
Mar 29, 2024	EFFECT	EFFECT
Mar 27, 2024	CORRESP	CORRESP
Mar 26, 2024	UPLOAD	UPLOAD
Mar 21, 2024	S-3	S-3
Mar 20, 2024	8-K	Current Report
Mar 20, 2024	424B3	Prospectus Filed
Mar 20, 2024	EFFECT	EFFECT
Mar 18, 2024	CORRESP	CORRESP
Mar 18, 2024	10-K	Annual Report
Mar 18, 2024	8-K	Current Report

Peers (Alternatives to Adverum Biotechnologies Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Adverum Biotechnologies Inc News

Latest updates

Adverum Biotechnologies Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2021Q4	2021Q3	2021Q2	2021Q1	2021Q1	2019Q4	2019Q3	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4
Revenue	-	-	-	-	3,600,000	1,800,000	-	-	-	7,500,000	5,083,333	2,666,667	250,000	70,000	833,000	493,000	6,146,000	461,000	463,000	463,000	462,000	488,000
Operating Expenses	-24.2%	26,158,000	34,529,000	33,065,000	33,839,000	33,940,000	34,419,000	38,522,000	44,538,000	36,143,000	-	19,653,000	17,333,000	16,829,000	24,306,000	20,396,000	18,162,000	-	-	-	-	-
S&GA Expenses	-21.1%	10,880,000	13,789,000	12,466,000	12,780,000	11,741,000	11,895,000	14,453,000	21,930,000	16,163,000	-	8,279,000	7,389,000	5,187,000	4,826,000	9,179,000	5,368,000	-	-	-	-	-
R&D Expenses	-26.3%	15,278,000	20,740,000	20,599,000	21,059,000	22,199,000	22,524,000	24,069,000	22,608,000	19,980,000	-	11,374,000	9,944,000	11,642,000	14,480,000	11,217,000	12,794,000	-	-	-	-	-
EBITDA Margin	-14.4%	-31.28	-27.34	-24.56	-23.38	-22.01	-18.78	-17.16	-20.14	-24.41	-31.19	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-6764.7%	-1,133,000	17,000	21,000	17,000	19,000	-	-	-	-	-	-	-	-	-1,300,000	-	-	-	-	-	-	-
Earnings Before Taxes	24.4%	-24,847,000	-32,868,000	-31,489,000	-29,039,000	-32,717,000	-34,409,000	-38,362,000	-44,333,000	-28,436,000	-	-18,925,000	-16,118,000	-15,659,000	-22,208,000	-	-	-14,789,000	-13,829,000	-	-	-
EBT Margin	-14.1%	-32.85	-28.79	-25.84	-24.51	-22.99	-19.41	-17.84	-20.98	-25.45	-32.36	-	-	-	-	-	-	-	-	-	-	-
Net Income	27.9%	-23,714,000	-32,885,000	-31,510,000	-29,056,000	-32,736,000	-34,409,000	-38,362,000	-44,333,000	-28,436,000	-	-18,925,000	-16,118,000	-15,659,000	-20,958,000	-18,810,000	-17,200,000	-	-	-	-	-
Net Income Margin	-13.0%	-32.55	-28.81	-25.86	-24.53	-23.00	-19.41	-22.80	-24.90	-26.91	-32.67	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	11.8%	-21,520,000	-24,408,000	-23,285,000	-22,497,000	-18,660,000	-30,167,000	-31,515,000	-37,563,000	-23,709,000	-23,657,000	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-12.1%	173	197	241	276	308	332	375	407	440	491	526	462	483	508	331	349	223	206	210	221	213
Current Assets	-17.5%	103	125	147	169	191	213	246	280	317	348	386	410	434	460	283	300	176	168	181	193	209
Cash Equivalents	-28.8%	75.00	105	111	68.00	68.00	84.00	92.00	90.00	37.00	33.00	47.00	45.00	63.00	73.00	27.00	130	67.00	74.00	99.00	145	156
Net PPE	-4.7%	15.00	15.00	32.00	33.00	35.00	37.00	38.00	37.00	33.00	37.00	32.00	28.00	28.00	27.00	27.00	27.00	25.00	15.00	6.00	4.00	4.00
Liabilities	-4.8%	90.00	94.00	110	118	127	124	131	124	124	145	147	47.00	48.00	43.00	49.00	45.00	48.00	41.00	32.00	33.00	12.00
Current Liabilities	-13.7%	25.00	29.00	45.00	46.00	32.00	29.00	31.00	23.00	21.00	25.00	21.00	20.00	21.00	16.00	21.00	17.00	19.00	18.00	10.00	11.00	11.00
Shareholder's Equity	-18.7%	83.00	103	131	158	182	208	244	283	316	346	379	415	434	465	283	304	175	164	178	188	201
Retained Earnings	-2.6%	-919	-896	-863	-831	-802	-769	-729	-686	-648	-613	-575	-531	-502	-464	-437	-407	-385	-366	-349	-335	-320
Additional Paid-In Capital	0.4%	1,004	999	995	990	986	980	976	970	965	960	955	946	937	930	720	713	561	531	528	524	523
Shares Outstanding	0.4%	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	-	-	-	-	-	-	-	-
Float	-	-	-	152	-	-	-	115	-	-	-	320	-	-	-	1,500	-	-	-	675	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	10.8%	-21,328	-23,913	-23,249	-22,412	-18,475	-31,808	-28,879	-28,929	-25,815	-25,796	-33,915	-22,305	-22,224	-26,544	-16,907	-13,616	-14,835	-9,530	-11,588	-13,217	-12,730
Share Based Compensation	-5.5%	4,148	4,389	4,469	4,563	5,253	4,503	4,942	5,381	4,410	5,326	8,234	7,224	6,177	6,020	4,785	3,409	2,850	2,661	2,626	1,762	1,182
Cashflow From Investing	-154.3%	-9,878	18,197	67,023	21,533	2,234	24,368	30,735	84,383	23,883	10,470	37,777	6,579	11,576	-132,373	-88,627	-70,743	-19,210	-15,016	-36,592	2,745	8,027
Cashflow From Financing	258.1%	166	-105	8.00	-	242	-	362	3.00	375	-	517	1,505	376	204,254	2,731	148,624	26,771	-91.00	1,881	-370	-21.00

ADVM Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
License revenue	$ 3,600	$ 0
Operating expenses:
Research and development	77,676	99,277
General and administrative	49,915	57,858
Total operating expenses	127,591	157,135
Operating loss	(123,991)	(157,135)
Other income, net	5,748	2,673
Net loss before income taxes	(118,243)	(154,462)
Income tax benefit (provision)	1,078	(74)
Net loss	(117,165)	(154,536)
Other comprehensive loss:
Net unrealized gain (loss) on marketable securities	1,057	(788)
Foreign currency translation adjustment	1	(29)
Comprehensive loss	$ (116,107)	$ (155,353)
Net loss per share - basic (in USD per share)	$ (1.16)	$ (1.56)
Net loss per share - diluted (in USD per share)	$ (1.16)	$ (1.56)
Weighted-average common shares outstanding - basic (in shares)	100,824	99,251
Weighted-average common shares outstanding - diluted (in shares)	100,824	99,251

ADVM Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 75,000	$ 68,431
Short-term investments	21,526	117,158
Prepaid expenses and other current assets	6,247	5,006
Total current assets	102,773	190,595
Operating lease right-of-use assets	52,266	78,934
Property and equipment, net	14,764	34,927
Restricted cash	1,976	2,503
Deposit and other long-term assets	1,231	1,413
Total assets	173,010	308,372
Current liabilities:
Accounts payable	1,921	2,238
Accrued expenses and other current liabilities	12,584	16,767
Lease liability, current portion	10,409	13,241
Total current liabilities	24,914	32,246
Long-term liabilities:
Lease liability, net of current portion	64,627	93,561
Other non-current liabilities	0	1,047
Total liabilities	89,541	126,854
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.0001 par value, 5,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.0001 par value, 300,000 shares authorized at December 31, 2023: 101,433 and 100,117 shares issued and outstanding at December 31, 2023 and 2022, respectively	10	10
Additional paid-in capital	1,003,709	985,651
Accumulated other comprehensive loss	(473)	(1,531)
Accumulated deficit	(919,777)	(802,612)
Total stockholders’ equity	83,469	181,518
Total liabilities and stockholders’ equity	$ 173,010	$ 308,372

About Adverum Biotechnologies Inc

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

CEO	Dr. Laurent Fischer
WEBSITE	https://adverum.com
INDUSTRY	Biotechnology
EMPLOYEES	123

Adverum Biotechnologies Inc Frequently Asked Questions

What is the ticker symbol for Adverum Biotechnologies Inc? What does ADVM stand for in stocks?

ADVM is the stock ticker symbol of Adverum Biotechnologies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Adverum Biotechnologies Inc (ADVM)?

As of Fri Apr 26 2024, market cap of Adverum Biotechnologies Inc is 190.95 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADVM stock?

You can check ADVM's fair value in chart for subscribers.

What is the fair value of ADVM stock?

You can check ADVM's fair value in chart for subscribers. The fair value of Adverum Biotechnologies Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Adverum Biotechnologies Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADVM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Adverum Biotechnologies Inc a good stock to buy?

The fair value guage provides a quick view whether ADVM is over valued or under valued. Whether Adverum Biotechnologies Inc is cheap or expensive depends on the assumptions which impact Adverum Biotechnologies Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADVM.

What is Adverum Biotechnologies Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, ADVM's PE ratio (Price to Earnings) is -1.63 and Price to Sales (PS) ratio is 53.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADVM PE ratio will change depending on the future growth rate expectations of investors.